Cargando…

Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)

OBJECTIVES: Asymptomatic and symptomatic patients may transmit severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), but their clinical features and immune responses remain largely unclear. We aimed to characterise the clinical features and immune responses of asymptomatic and symptomatic pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Chuanhao, Wang, Yali, Hu, Min, Wen, Lingjun, Wen, Chuan, Wang, Yang, Zhu, Weihong, Tai, Shi, Jiang, Zhongbiao, Xiao, Kui, Faria, Nuno Rodrigues, De Clercq, Erik, Xu, Junmei, Li, Guangdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519951/
https://www.ncbi.nlm.nih.gov/pubmed/33005417
http://dx.doi.org/10.1002/cti2.1182
_version_ 1783587676280061952
author Jiang, Chuanhao
Wang, Yali
Hu, Min
Wen, Lingjun
Wen, Chuan
Wang, Yang
Zhu, Weihong
Tai, Shi
Jiang, Zhongbiao
Xiao, Kui
Faria, Nuno Rodrigues
De Clercq, Erik
Xu, Junmei
Li, Guangdi
author_facet Jiang, Chuanhao
Wang, Yali
Hu, Min
Wen, Lingjun
Wen, Chuan
Wang, Yang
Zhu, Weihong
Tai, Shi
Jiang, Zhongbiao
Xiao, Kui
Faria, Nuno Rodrigues
De Clercq, Erik
Xu, Junmei
Li, Guangdi
author_sort Jiang, Chuanhao
collection PubMed
description OBJECTIVES: Asymptomatic and symptomatic patients may transmit severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), but their clinical features and immune responses remain largely unclear. We aimed to characterise the clinical features and immune responses of asymptomatic and symptomatic patients infected with SARS‐CoV‐2. METHODS: We collected clinical, laboratory and epidemiological records of patients hospitalised in a coronavirus field hospital in Wuhan. We performed qualitative detection of anti‐SARS‐CoV‐2 immunoglobulin M (IgM) and immunoglobulin G (IgG) using archived blood samples. RESULTS: Of 214 patients with SARS‐CoV‐2, 26 (12%) were asymptomatic at hospital admission and during hospitalisation. Most asymptomatic patients were ≤ 60 years (96%) and females (65%) and had few comorbidities (< 16%). Serum levels of white and red blood cells were higher in asymptomatic than in symptomatic patients (P‐values < 0.05). During hospitalisation, IgG seroconversion was commonly observed in both asymptomatic and symptomatic patients (85% versus 94%, P‐value = 0.07); in contrast, IgM seroconversion was less common in asymptomatic than in symptomatic patients (31% versus 74%, P‐value < 0.001). The median time from the first virus‐positive screening to IgG or IgM seroconversion was significantly shorter in asymptomatic than in symptomatic patients (median: 7 versus 14 days, P‐value < 0.01). Furthermore, IgG/IgM seroconversion rates increased concomitantly with the clearance of SARS‐CoV‐2 in both asymptomatic and symptomatic patients. At the time of virus clearance, IgG/IgM titres and plasma neutralisation capacity were significantly lower in recovered asymptomatic than in recovered symptomatic patients (P‐values < 0.01). CONCLUSION: Asymptomatic and symptomatic patients exhibited different kinetics of IgG/IgM responses to SARS‐CoV‐2. Asymptomatic patients may transmit SARS‐CoV‐2, highlighting the importance of early diagnosis and treatment.
format Online
Article
Text
id pubmed-7519951
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75199512020-09-30 Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Jiang, Chuanhao Wang, Yali Hu, Min Wen, Lingjun Wen, Chuan Wang, Yang Zhu, Weihong Tai, Shi Jiang, Zhongbiao Xiao, Kui Faria, Nuno Rodrigues De Clercq, Erik Xu, Junmei Li, Guangdi Clin Transl Immunology Original Article OBJECTIVES: Asymptomatic and symptomatic patients may transmit severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), but their clinical features and immune responses remain largely unclear. We aimed to characterise the clinical features and immune responses of asymptomatic and symptomatic patients infected with SARS‐CoV‐2. METHODS: We collected clinical, laboratory and epidemiological records of patients hospitalised in a coronavirus field hospital in Wuhan. We performed qualitative detection of anti‐SARS‐CoV‐2 immunoglobulin M (IgM) and immunoglobulin G (IgG) using archived blood samples. RESULTS: Of 214 patients with SARS‐CoV‐2, 26 (12%) were asymptomatic at hospital admission and during hospitalisation. Most asymptomatic patients were ≤ 60 years (96%) and females (65%) and had few comorbidities (< 16%). Serum levels of white and red blood cells were higher in asymptomatic than in symptomatic patients (P‐values < 0.05). During hospitalisation, IgG seroconversion was commonly observed in both asymptomatic and symptomatic patients (85% versus 94%, P‐value = 0.07); in contrast, IgM seroconversion was less common in asymptomatic than in symptomatic patients (31% versus 74%, P‐value < 0.001). The median time from the first virus‐positive screening to IgG or IgM seroconversion was significantly shorter in asymptomatic than in symptomatic patients (median: 7 versus 14 days, P‐value < 0.01). Furthermore, IgG/IgM seroconversion rates increased concomitantly with the clearance of SARS‐CoV‐2 in both asymptomatic and symptomatic patients. At the time of virus clearance, IgG/IgM titres and plasma neutralisation capacity were significantly lower in recovered asymptomatic than in recovered symptomatic patients (P‐values < 0.01). CONCLUSION: Asymptomatic and symptomatic patients exhibited different kinetics of IgG/IgM responses to SARS‐CoV‐2. Asymptomatic patients may transmit SARS‐CoV‐2, highlighting the importance of early diagnosis and treatment. John Wiley and Sons Inc. 2020-09-26 /pmc/articles/PMC7519951/ /pubmed/33005417 http://dx.doi.org/10.1002/cti2.1182 Text en © 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jiang, Chuanhao
Wang, Yali
Hu, Min
Wen, Lingjun
Wen, Chuan
Wang, Yang
Zhu, Weihong
Tai, Shi
Jiang, Zhongbiao
Xiao, Kui
Faria, Nuno Rodrigues
De Clercq, Erik
Xu, Junmei
Li, Guangdi
Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
title Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
title_full Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
title_fullStr Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
title_full_unstemmed Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
title_short Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
title_sort antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (sars‐cov‐2)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519951/
https://www.ncbi.nlm.nih.gov/pubmed/33005417
http://dx.doi.org/10.1002/cti2.1182
work_keys_str_mv AT jiangchuanhao antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2
AT wangyali antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2
AT humin antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2
AT wenlingjun antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2
AT wenchuan antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2
AT wangyang antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2
AT zhuweihong antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2
AT taishi antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2
AT jiangzhongbiao antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2
AT xiaokui antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2
AT farianunorodrigues antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2
AT declercqerik antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2
AT xujunmei antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2
AT liguangdi antibodyseroconversioninasymptomaticandsymptomaticpatientsinfectedwithsevereacuterespiratorysyndromecoronavirus2sarscov2